

Comparison of Deferoxamine, Activated Charcoal, and Vitamin C in Changing the Serum Level of Fe in Iron Overloaded Rats

Reza Ghafari¹, Jaber Gharehdaghi², Hassan Solhi*³

Received: 20.06.2013

Accepted: 27.06.2013

ABSTRACT

Background: Iron is an essential mineral for normal cellular physiology but its overload can lead to cell injury. For many years, deferoxamine injection has been used as an iron chelator for treatment of iron overload. The aim of this study is to compare oral deferoxamine, activated charcoal, and vitamin C, as an absorbent factor of Fe, in changing the serum level of iron in iron overload rats.

Methods: In this experimental study, all groups were administered 150 mg iron dextran orally by gavage. After eight hours, rats in the first group received oral deferoxamine while those in the second and third groups received oral activated charcoal 1 mg/kg and oral vitamin C 150 mg, respectively. Then, serum levels of iron were measured in all rats.

Results: The mean serum level of iron in rats that received oral deferoxamine was 258.11 ± 10.49 $\mu\text{g/dl}$, whereas mean levels of iron in charcoal and vitamin C groups were 380.88 ± 11.21 $\mu\text{g/dl}$ and 401.22 ± 13.28 $\mu\text{g/dl}$, respectively. None of the measurements were within safety limits of serum iron.

Conclusion: It seems that oral deferoxamine per se may not help physicians in the management of cases presented with iron toxicity. Activated charcoal did not reduce serum iron significantly in this study and further investigations may be warranted to assess the potential clinical utility of its mixture with oral deferoxamine as an adjunct in the clinical management of iron ingestions.

Keywords: Ascorbic Acid, Charcoal, Deferoxamine, Iron, Poisoning, Rats.

IJT 2014; 940-943

INTRODUCTION

Iron is an essential mineral for normal cellular physiology but its overload will lead to cell injury. Compared to iron deficiency, conditions associated with iron excess are less frequent but high contents of tissue iron can lead to liver and heart diseases [1], cancer [2], neurodegenerative disorders [3], diabetes [4], hormonal abnormalities [5], and immune system abnormalities [6]. The conditions which can lead to iron overload include: (a) Primary hemochromatosis, a genetic disorder associated with increased intestinal absorption of iron; (b) high dietary iron intake; and (c) frequent blood transfusions. Cases of acute iron toxicity are rare and often present with hepatotoxicity [7]. Mammals have numerous and integrated mechanisms for regulation of

iron metabolism [8]. There is an efficient iron control system in humans that absorbs and excretes 1 mg of Fe per day. On the other hand, there is no mechanism to remove the excess iron [9]. Therefore, when body accumulates excessive amounts of iron, in the absence of effective treatment, body iron progressively increases and produces deposits in the liver, pancreas, heart, and other organs. Without intervention, metal accumulation will lead to liver disease with progression to cirrhosis, pancreas injury (e.g. diabetes), and cardiomyopathy [10].

For many years, deferoxamine injections have been used as an iron chelator for treatment of beta thalassemia and other conditions with iron overload [11, 12]. Although this drug is effective in excretion of Fe, it needs long subcutaneous infusions (12-

1. MD student, Arak University of Medical Sciences, Arak, Iran.

2. Department of Legal Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.

3. Department of Forensic Medicine, Arak University of Medical Sciences, Arak, Iran.

*Corresponding Author: E-mail: solhi.h@arak.ac.ir

24 hr/day, 5-6 days/week) and it is expensive [13].

In cases of excessive iron ingestion, prevention of gastrointestinal (GI) absorption (GI decontamination) with activated charcoal can also be used [14]. It is produced through heating wood paste at 900°C and then rinsing with water. Then charcoal becomes activated by strong acids. Each gram of this substance has approximately 1000 m² surface area which can sop up numerous drugs and poisons and prevent their absorption into systemic circulation. If it is administered within 1 hour after ingestion of certain poisons, it would effectively prevent their absorption. Constipation is the most notable side effect of activated charcoal [15].

On the other hand, initial evidence suggests that ascorbic acid can enhance iron absorption. It has been emphasized in several studies that ascorbic acid increase Fe absorption from 3.7 to 10.4% [16, 17].

Hence, the aim of this study was to compare oral deferoxamine, activated charcoal, and vitamin C as an absorbent factor of Fe in changing serum levels of Fe after ingestion of iron in rats.

MATERIALS AND METHODS

This experimental study included 27 Sprague–Dawley rats weighing 250-300 g randomly divided into three groups. The animals were fed with a standard rat pellet diet for 2 weeks as acclimation period. During this period, they had access to water ad libitum, with alternate 12-h dark/light cycle; and the ambient temperature held constant between 21 and 25°C. None of the rats were excluded and there was no mortality.

All animals were administered 150 mg iron dextran orally by gavage. Immediately, rats in the first group received oral deferoxamine while those in the second and third groups received oral activated charcoal 1 mg/kg and oral vitamin C 150 mg. For blood sampling, nearly 1.8 ml of blood was collected through iliac vein from each rat. Then, after eight hours, serum levels of iron were measured in all rats.

This study was approved by the local Ethics Committee of Arak University of Medical Sciences, Arak, Iran. The collected

data were analyzed by student's t-test using SPSS statistical software version 16.0.

RESULTS

Serum concentration of Iron was evaluated in all three groups. The mean serum level of Fe in rats that received oral deferoxamine was 258.11±10.49 µg/dl while in charcoal and vitamin C groups, this value was 380.88±11.21 µg/dl and 401.22±13.28 µg/dl, respectively. Details of measurements are presented in Table 1.

Table 1. Serum concentration of Fe in groups (µg/dl).

Group	Mean±SD
Deferoxamine	258.11±10.49 µg/dl
Charcoal	380.88±11.21 µg/dl
Vitamin C	401.22±13.28 µg/dl

Mean serum level of iron in the deferoxamine group was significantly lower than the other two groups. The paired sample t-test showed that there was a statically significant difference between the mean concentrations of Fe between the deferoxamine group and activated charcoal group (P<0.0001) and also vitamin C group (P<0.0001).

The comparison between the other two groups also revealed that the mean serum levels of iron in charcoal group were significantly lower than the vitamin C group (P=0.006).

DISCUSSION

The results of the present study showed that oral deferoxamine significantly lowers the amounts of serum Fe in comparison to oral activated charcoal. Although serum levels of Fe in the deferoxamine group were lower than the other groups, the iron concentration achieved in the present study was not within safety limits [18, 19].

Although these findings were consistent with those in previous studies [20], they contradict the findings of Gomez *et al.* who reported the prevention of iron absorption by

a slurry containing deferoxamine and activated charcoal [13].

Deferoxamine is a drug that is created by the bacterial fermentation of *Streptomyces pilosus* species [21]. One molecule of this compound can bind to a three-valence iron ion and form ferrioxamine complex which is biologically inactive [21]. In cases of oral administration of deferoxamine, this complex forms in the gut and because of its low gastrointestinal absorption [15], its excretion increases [22]. GI absorption of deferoxamine is too low and the small amount that is absorbed is rapidly eliminated from the blood stream [21]. Since the mechanism of iron absorption from the digestive tract is similar in humans and in rats [19], the results of the present study have comparable bearing in humans.

Trials to substitute oral deferoxamine instead of subcutaneous infusion have shown that oral administration can be effective in removing iron from GI tract [18]; however, it should be noted that systemic absorption of oral deferoxamine is very low and, as a result, the excretion of absorbed iron as compared to infusion form of deferoxamine is very low [18]. In laboratory trials with guinea pigs, oral deferoxamine therapy was successful in preventing or delaying death, depending on the elapsed time of administration following ingestion [23]. However, the efficacy of oral deferoxamine in humans for iron poisoning has not been established [24].

Activated charcoal has been used to adsorb ingested iron and is likely to be effective especially in ferrous sulfate overdose but it is not used often because of the widely-held belief that it binds poorly to iron [25]. In contrast, Eshel *et al.* reported that activated charcoal had no effect on iron absorption in rats. In their study, deferoxamine and activated charcoal did not alter iron absorption from the digestive tract [19]. They found that serum iron concentrations measured 1 hour after treatment were as high as those found in the untreated control groups. Despite the fact that most studies using deferoxamine or activated charcoal did not show any significant effect on iron excretion, Gomez *et al.* found that a premixed deferoxamine and

activated charcoal slurry could decrease GI absorption of ferrous sulfate [14].

CONCLUSION

In summary, it seems that oral deferoxamine may help physicians in management of cases presented with iron toxicity. In the present study, activated charcoal did not reduce serum iron significantly and further investigations may be warranted to assess the potential clinical utility of its mixture with oral deferoxamine as an adjunct in the clinical management of iron ingestions.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge Zahra Rajabi for her technical assistance.

REFERENCES

1. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. *Atherosclerosis*. 2001;154(3):739-46.
2. Parkkila S, Niemelä O, Savolainen ER, Koistinen P. HFE mutations do not account for transfusional iron overload in patients with acute myeloid leukemia. *Transfusion*. 2001;41(6):828-31.
3. Sayre L, Perry G, Atwood C, Smith M. The role of metals in neurodegenerative diseases. *Cellular and molecular biology (Noisy-le-Grand, France)*. 2000;46(4):731-41.
4. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. *The Lancet*. 2001;358(9291):1405-9.
5. Wilkinson H. Haemochromatosis associated with arthritis and hypopituitarism. *Annals of clinical biochemistry*. 1996;33:171-3.
6. YinPeng L, Peng L. Impact of salinity on accumulation of several metal elements in *Bruguiera gymnorhiza* seedlings and the effect of Ca. *Chinese Journal of Applied Ecology*. 2000;11(2):177-80.
7. Tenenbein M. Hepatotoxicity in acute iron poisoning. *Clinical Toxicology*. 2001;39(7):721-6.

8. Fraga CG, Oteiza PI. Iron toxicity and antioxidant nutrients. *Toxicology*. 2002;180(1):23-32.
9. Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. *Biometals*. 2011;24(2):239-58.
10. Brittenham GM. Pyridoxal Isonicotinoyl Hydrazone. *Annals of the New York Academy of Sciences*. 1990;612(1):315-26.
11. Lombardo T, Ferro G, Frontini V, Percolla S. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. *American journal of hematology*. 1996;51(1):90-2.
12. Giardina PJ, Grady RW, editors. Chelation therapy in β -thalassemia: an optimistic update. *Seminars in hematology*; 2001;38(4):360-6.
13. Giardina PJ, Grady RW, editors. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. *Seminars in hematology*; 1995;32(4):304-12.
14. Gomez HF, McClafferty HH, Flory D, Brent J, Dart RC. Prevention of gastrointestinal iron absorption by chelation from an orally administered premixed deferoxamine/charcoal slurry. *Annals of emergency medicine*. 1997;30(5):587-92.
15. Norouzi A, Rajabi R, Rajabalipour F, Solhi H, Alimoradian A. Comparison of Activated Charcoal and Industrial Charcoal in Prevention of GI Absorption of Diazepam. 2012;2(4):124-7.
16. Layrisse M, Martínez-Torres C, González M. Measurement of the total daily dietary iron absorption by the extrinsic tag model. *The American Journal of Clinical Nutrition*. 1974;27(2):152-62.
17. Rossander L, Hallberg L, Björn-Rasmussen E. Absorption of iron from breakfast meals. *The American Journal of Clinical Nutrition*. 1979;32(12):2484-9.
18. Jackson TW, Ling LJ, Washington V. The effect of oral deferoxamine on iron absorption in humans. *Clinical Toxicology*. 1995;33(4):325-9.
19. Eshel G, Barr J, Chazan S, Tavori I, Kariv N, Schejter A, et al. Efficacy of orally administered deferoxamine, activated charcoal, and sodium bicarbonate in acute iron intoxication in rats: implications for the treatment of pediatric iron poisoning. *Current therapeutic research*. 2000;61(9):648-56.
20. Tennebein M, Wiseman N, Yatscoff RW. Gastrotomy and whole bowel irrigation in iron poisoning. *Pediatric emergency care*. 1991;7(5):286-8.
21. Fauci AS. *Harrison's principles of internal medicine*: McGraw-Hill Medical New York; 2008.
22. Bergeron RJ, Wiegand J, Brittenham GM. HBED: a potential alternative to deferoxamine for iron-chelating therapy. *Blood*. 1998;91(4):1446-52.
23. McEnery JT. Hospital management of acute iron ingestion. *Clinical Toxicology*. 1971;4(4):603-13.
24. Anderson AC. Iron poisoning in children. *Current Opinion in Pediatrics*. 1994;6(3):289-94.
25. Chyka P, Butler A, Herman M. Ferrous sulfate adsorption by activated charcoal. *Veterinary and human toxicology*. 2001;43(1):11-3.